September 24th, 2024 (Shanghai) — We are glad to announce that Dr. Xiaole Shirley Liu, the Co-founder and Chief Executive Officer of GV20 Therapeutics, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase from September 24th to 25th, and 27th, 2024. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the Western biopharma industry.
About GV20 Therapeutics
GV20 Therapeutics is a clinical-stage AI-based next-generation biotherapeutics company. Its lead program GV20-0251, is a first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting a novel immune checkpoint IGSF8 to activate innate and adaptive immunity. It is the world’s first AI-designed antibody against an AI-predicted target in the clinic. The power of GV20’s AI platform is demonstrated by GV20-0251’s unprecedented 3-year timeline from target research to IND, and validated by GV20-0251’s favorable safety and promising monotherapy efficacy in a multi-center Phase 1/2 clinical trial in patients with advanced solid tumors (NCT05669430). GV20’s discovery pipeline includes best-in-class and first-in-class ADCs and degraders. To learn more about GV20, please visit https://gv20tx.com/ and follow the company on LinkedIn: https://www.linkedin.com/company/gv20tx/.
About the speaker
Dr. X. Shirley Liu is the co-founder and CEO of GV20 Therapeutics, a clinical-stage AI-based next-generation biotherapeutics company. Dr. Liu received her PhD in Biomedical Informatics and PhD minor in Computer Science from Stanford University in 2002. Before joining GV20, she was a Professor of Biostatistics and Computational Biology at the Department of Data Science at Dana-Farber Cancer Institute (DFCI) and Harvard University. She has published over 270 papers and has an H-index of 123. She is a fellow of the International Society of Computational Biology (ISCB), the American Institute for Medical and Biological Engineering (AIMBE), and was a Breast Cancer Research Foundation Investigator (2017-2021). She is a recipient of the Sloan Research Fellowship (2008), the Weitzman Outstanding Early Career Investigator Award from the Endocrine Society (2016), the ISCB Innovator Award (2020), and the Benjamin Franklin Award for Open Access in the Life Sciences (2020). Her lab has mentored 28 PhD and postdoctoral trainees to independent academic careers.
About ACCESS CHINA Partnering Forum
ACCESS CHINA Partnering Forum – Autumn Virtual Showcase is scheduled to be held on September 24th to 25th, and 27th, 2024, via Zoom webinar. This event helps biotechs/pharmas efficiently present their assets in front of 500+ healthcare companies and VCs online. During the event, audience can have access to innovative pharma and healthcare products from worldwide.
Conference Name: ACCESS CHINA Partnering Forum
Date & Time: Sep 24 – 25 (live), and 27 (VoD) 2024, China time
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 500+ participants Online; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs
View more information at https://biotochina.org/
REGISTER
To Register for ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
BioToChina.org 